Humacyte Inc (HUMA) is a groundbreaking biotechnology firm at the forefront of vascular and regenerative medicine, specializing in the development of human acellular vessels (HAVs). These innovative, off-the-shelf products are designed to meet pressing needs in vascular reconstruction and chronic disease management, improving patient outcomes and potentially reducing healthcare expenses. Leveraging its advanced technology platform, Humacyte is strategically positioned to drive innovation in transplantation and tissue engineering, thereby cementing its status as a transformative leader within the rapidly evolving landscape of medical therapies.
| Revenue (TTM) | $2.12M |
| Gross Profit (TTM) | $-79.37M |
| EBITDA | $-103.23M |
| Operating Margin | -6649.00% |
| Return on Equity | -548.00% |
| Return on Assets | -49.90% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.11 |
| Price-to-Book | 5.01 |
| Price-to-Sales (TTM) | 57.56 |
| EV/Revenue | 67.3 |
| EV/EBITDA | 4.34 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 34.90% |
| Shares Outstanding | $277.80M |
| Float | $250.79M |
| % Insiders | 5.67% |
| % Institutions | 26.87% |
Volatility is currently expanding
– Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end of the second quarter to 49 as of September 30, 2026. – Commercial momentum continues to build, driven by expanding hospital orders and surgeon interest.
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.36, signifying a -7.88% move from its prior day's close.
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.48, signifying a -4.26% move from its prior day's close.
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.5, signifying a -2.86% move from its prior day's close.
DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the addition of life science industry veterans Scott Coward and Paul Kuznik to the Company's Board of Directors, both of whom bring substantial experience in the areas of commercialization, enterprise leadership, and global operations.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D.
– FDA authorizes extension of Symvess expiration dating from 18 months to 36 months – – Extended shelf life supported by additional stability data demonstrating Symvess continues to meet all established quality specifications throughout the 36-month dating period – DURHAM, N.C., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered human tissues, today announced that the U.S. Food and Drug Administration (FDA) has authorized an extension of the expiration dating period for Symvess® (acellular tissue engineered vessel-tyod, or ATEV) from 18 months to 36 months when stored refrigerated at 2°C to 8°C (36°F to 46°F).
– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 –
– Phase 3 results highlight benefits of ATEV for patients at higher risk of fistula failure, including all women and men with obesity and diabetes –
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HUMA and any ticker you trade — then tracks every position and per-strategy win rate.
